Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genitourinary cancers: molecular determinants for personalized therapies.
Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Raspollini MR, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Mazzucchelli R, et al. Among authors: scarpelli m. Urologia. 2016 Sep 26;83(3):107-109. doi: 10.5301/uro.5000187. Epub 2016 Jun 23. Urologia. 2016. PMID: 27338983
Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Lopez-Beltran A, et al. Among authors: scarpelli m. Curr Drug Targets. 2015;16(2):115-24. doi: 10.2174/1389450116666150204115756. Curr Drug Targets. 2015. PMID: 25654736 Review.
Present and future of personalized medicine in adult genitourinary tumors.
Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R. Ciccarese C, et al. Among authors: scarpelli m. Future Oncol. 2015;11(9):1381-8. doi: 10.2217/fon.15.30. Future Oncol. 2015. PMID: 25952784 Review.
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. Piva F, et al. Among authors: scarpelli m. Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
Immunotargeting and personalized therapies in genitourinary cancers.
Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Ciccarese C, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Mazzucchelli R, et al. Among authors: scarpelli m. Future Oncol. 2016 Aug;12(16):1853-6. doi: 10.2217/fon-2016-0183. Epub 2016 Apr 26. Future Oncol. 2016. PMID: 27113700 No abstract available.
Pathology and molecular updates in tumors of the prostate: towards a personalized approach.
Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. Gasparrini S, et al. Among authors: scarpelli m. Expert Rev Mol Diagn. 2017 Aug;17(8):781-789. doi: 10.1080/14737159.2017.1341314. Epub 2017 Jun 15. Expert Rev Mol Diagn. 2017. PMID: 28598696 Review.
512 results